Skip to main content
S&P 5007,807.46-0.05%DOW51,853.46+0.38%NASDAQ27,277.31-0.32%BTC$82,763.00-1.36%ETH$2,528.20-0.78%GOLD$4,187.30-0.69%OIL$93.72+2.04%
Smart Investors Daily
SID Premium
SI

NASDAQ · SION

Sionna Therapeutics, Inc.

Healthcare · Biotechnology

$4.90

Down-$0.11 (-2.24%)

Updated Oct 12, 2026, 4:43 PM

SID Score

2.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.86B
P/E ratio
-31.26
Dividend yield
0.00%
52-week range
$4.01 – $54.97
Volume
633.56K
Avg. volume
293.9K

Price performance · SION

SION price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 9, 2026

SION closed at $4.90 after 20 trading sessions, down 40.68% for the selected period.

Last close
$4.90
Period change
-40.68%
Period low
$4.75
Period high
$8.26
Daily close
View OHLC price history
SION OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 9, 2026$4.93$5.12$4.83$4.90633.56K
Oct 8, 2026$4.78$4.97$4.65$4.90915.6K
Oct 7, 2026$4.68$4.87$4.61$4.82880.22K
Oct 6, 2026$4.88$4.88$4.52$4.751.26M
Oct 5, 2026$4.95$4.96$4.63$4.851.1M
Oct 2, 2026$5.19$5.19$4.86$4.911.16M
Oct 1, 2026$5.26$5.33$5.03$5.101.06M
Sep 30, 2026$5.19$5.3421$5.02$5.261.16M
Sep 29, 2026$5.15$5.19$5.025$5.15797.86K
Sep 28, 2026$5.17$5.25$5.05$5.12775.82K
Sep 25, 2026$5.28$5.30$5.09$5.231.4M
Sep 24, 2026$5.50$5.59$5.1521$5.231.25M
Sep 23, 2026$6.03$6.1199$5.32$5.511.67M
Sep 22, 2026$5.99$6.17$5.84$6.021.69M
Sep 21, 2026$6.00$6.13$5.70$6.002.52M
Sep 18, 2026$7.12$7.19$5.90$5.963.7M
Sep 17, 2026$7.27$7.73$7.15$7.181.48M
Sep 16, 2026$6.95$7.3681$6.91$7.041.97M
Sep 15, 2026$7.87$8.00$6.85$6.882.46M
Sep 14, 2026$7.84$8.535$7.84$8.261.22M

Latest SION news

The latest Smart Investors Daily articles mentioning SION.

Stock researchCompany · Overview

SION research

Overview

Company profile and research snapshot.

Company profile

Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefit to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$34.50
Implied upside
—
Analysts
—
SION recent ratings
DateFirmRatingTarget
Sep 15, 2026WedbushNeutral—
Aug 11, 2026GuggenheimNeutral—
Aug 11, 2026WedbushNeutral—
Aug 10, 2026BTIGNeutral—
Aug 7, 2026GuggenheimBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 17, 2026

Sionna Therapeutics (SION) Approves 46% Job Cut. Can a New Trial Make its Cash More Productive?

Sionna Therapeutics, Inc. (NASDAQ:SION) announced on September 14 that its board approved an approximately 46% workforce reduction as it concentrates development on SION-451 plus SION-2222 for cystic fibrosis. Sionna Therapeutics, Inc. (NASDAQ:SION) ended the second quarter with approximately $268.3 million in cash, cash equivalents, and marketable securities. Management estimates that the workforce reduction, discontinued investment […]

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By